Endogena therapeutics secures fda green light for breakthrough amd treatment

San francisco and toronto and zurich, switzerland, oct. 24, 2023 (globe newswire) -- endogena therapeutics inc., a pioneering biotech company dedicated to revolutionizing regenerative medicine, is proud to announce a significant achievement that holds the promise of transforming lives. the u.s. food and drug administration (fda) has granted clearance for endogena's investigational new drug (ind) application, opening the door to a groundbreaking clinical investigation of ea 2351. this innovative compound offers hope to patients battling geographic atrophy (ga), an advanced form of age-related macular degeneration (amd). the eagerly awaited first-in-human study is set to commence in 2024.
AMD Ratings Summary
AMD Quant Ranking